Premium
Oxyntomodulin: a potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man
Author(s) -
SCHJOLDAGER B. T. G.,
BALDISSERA F. G. A.,
MORTENSEN P. E.,
HOLST J. J.,
CHRISTIANSEN J.
Publication year - 1988
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/j.1365-2362.1988.tb01046.x
Subject(s) - medicine , endocrinology , pentagastrin , glucagon , insulin , pharmacokinetics , chemistry , gastric inhibitory polypeptide , hormone , gastric acid , peptide hormone , gastrointestinal hormone , secretion
Synthetic oxyntomodulin, a predicted product of the glucagon gene, which is produced in the human lower intestinal mucosa, was infused in doses of 100 and 400 ng kg ‐1 h ‐1 into six volunteers to study its pharmacokinetics and effects on pentagastrin‐stimulated gastric acid secretion (100 ng kg ‐1 h ‐1 ). The concentration of oxyntomodulin in plasma measured with a cross‐reacting glucagon assay increased from 37 ± 5 to 106 ± 17 and 301 ± 40 pmol l ‐1 , respectively. The metabolic clearance rate was 5·2 ± 0·7 ml kg ‐1 min ‐1 and the half‐life in plasma was 12 ± 1 min. Oxyntomodulin reduced the pentagastrin‐stimulated acid secretion by 20 ± 9% during the low‐rate infusion ( P < 0·05) and by 76 ± 10% during the high‐rate infusion ( P < 0·05). In accordance with the homology with glucagon, there was a small, significant rise in plasma concentrations of insulin and insulin C‐peptide during oxyntomodulin infusion. Oxyntomodulin may therefore be included among the potential incretins and enterogastrones in man.